Trastuzumab deruxtecan

Where the papers sit

9 papers from the last 6 months study trastuzumab deruxtecan directly · updated from PubMed 1 Nov 2026

• Metastatic HER2 Breast Cancer

  Metastatic HER2-low and HER2-positive breast cancer care is moving toward more individualized treatment selection and toxicity management. Baseline albumin, imaging, histologic grade and clinical stage are being explored as predictors of severe adverse events or chemoresistance. Radiotherapy with trastuzumab deruxtecan and rechallenge after progression remain clinically relevant but require careful patient selection. S100-RAGE signaling offers a mechanistic explanation for intrinsic resistance and a possible therapeutic target.

  5 papers · 55.6%

• HER2-Targeted Lung Cancer Therapy

  HER2-altered lung cancer treatment is shifting toward matching antibody-drug conjugates and tyrosine-kinase inhibitors to the underlying alteration. Trastuzumab deruxtecan is being evaluated against conventional therapy in advanced NSCLC and as blockade after or before agents such as zongertinib. EGFR ectodomain mutations and ERBB2 signaling highlight receptor cross-talk as a route to cetuximab resistance. Sequencing strategies and the durability of responses remain open clinical questions.

  3 papers · 33.3%

• Residual Disease in Triple-Negative Breast Cancer

  Residual disease after neoadjuvant chemotherapy remains the central risk marker in triple-negative breast cancer. Molecular evaluation is being used to refine prognosis beyond pathological response alone. Recurring signals include immune biology, interferon activity and MHC class I expression. The work supports better selection of patients for intensified adjuvant strategies, although the most predictive markers remain unsettled.

  1 papers · 11.1%